Immunotherapy of HIV-infected Patients An Open, Dose-escalating Assessment of Vacc-C5 With Either GM-CSF or Alhydrogel as Adjuvant in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Trial Profile

Immunotherapy of HIV-infected Patients An Open, Dose-escalating Assessment of Vacc-C5 With Either GM-CSF or Alhydrogel as Adjuvant in HIV-1-infected Subjects on Antiretroviral Therapy (ART).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Vacc-c5 (Primary) ; Vacc-c5 (Primary) ; Aluminium hydroxide; Antiretrovirals; Granulocyte macrophage colony stimulating factor
  • Indications HIV infections
  • Focus Adverse reactions; Biomarker
  • Sponsors Bionor Immuno
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2017 Results from this trial have been published in BMC infectious diseases, according to a Bionor media release.
    • 21 Sep 2016 According to a Bionor media release, the company will present data from this study at 18th Institute of Human Virology Annual Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top